866-997-4948(US-Canada Toll Free)

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Published By :

Transparency Market Research

Published Date : Sep 2014

Category :

Therapeutic Area

No. of Pages : 121 Pages

 

This report on hospital infection therapeutics, studies the current as well as future prospects of the market globally. Hospital infections are also referred to as healthcare-associated infections (HCAIs), or nosocomial infections or hospital-acquired infection (HAIs). HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission. A Hospital infection also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Several antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally prevalent at present. This report comprises of an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments that are contained in the report. It also provides an overall information and data analysis of the global hospital infection therapeutics market with respect to market segments based on type of drugs used, major hospital infections and geographic regions.

 

The market for hospital infection therapeutics is segmented into three major therapeutic drug types, namely, antibacterial, antiviral and antifungal drugs. The hospital infection therapeutics market is also segmented on the basis of major hospital infection types, into six major categories, namely, hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. The market has been extensively analyzed on the basis of the usefulness, effectiveness and sales revenue of major drug types as well as geographic prevalence of major types of hospital infections. The market size and forecast in terms of USD million for each drug as well as major infection types has been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. 

 

Geographically, the hospital infection therapeutics market has been categorized into four regions namely, North America, Europe, Asia Pacific, and Rest of the World (ROW). The market size and forecast for each of these regions has been provided for the period 2012 to 2020 along with the CAGR for the forecast period 2014 to 2020. The report also comprises a section on pipeline analysis for this market that includes sales forecast for various drugs currently under phase III clinical trials and expected to be launched during the forecast period. Major pipeline drugs that have been included in the report are Amikacin Inhale, CAZ AVI, Ceftolozane/Tazobactam, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin and Tedizolid. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of this market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter’s five forces analysis and competitive analysis of the key players in 2013 in the global hospital infection therapeutics market.

 

A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the hospital infection therapeutics market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi.

 

The global hospital infection therapeutics market is segmented as follows:

 

Hospital Infection Therapeutics Market, by Drug Type

 

  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs

 

Hospital Infection Therapeutics Market, by Major Infections

 

  • Hospital-Acquired Pneumonia
  • Surgical Site Infections
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Other Hospital Infections

 

Hospital Infection Therapeutics Market, by Geography

 

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents

 

Chapter 1 Introduction

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 Assumptions

 

Chapter 2 Executive Summary

2.1 Market Snapshot: Global Hospital Infection Therapeutics Market

2.2 Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)

 

Chapter 3 Hospital Infection Therapeutics Market Overview

3.1 Introduction

3.2 Event Impact Analysis

3.3 Market Drivers

3.3.1 High Prevalence of Various Hospital Infections Driving the Demand for Anti-infective Drugs

3.3.2 High Susceptibility of Neonatal Population in a Healthcare Setting Giving Rise to Different Hospital Infections

3.3.3 Lack of Skilled Nursing Staff in Developing and Underdeveloped Economies is Increasing the Prevalence of HAIs

3.4 Market Restraints

3.4.1 Increasing Hospital Surveillance and Infection Control Programs in Developed Countries Leading to a Decline in Number of Hospital Infections

3.4.2 Increasing Number of Multi-drug resistant Bacterial Strains making Presently Available Antibacterial Drugs Obsolete

3.5 Market Opportunities

3.5.1 High Number of Pipeline Drug Molecules for Specific Treatment of HAIs

3.5.2 Increasing Incidences of Hospital Infections and High Unmet Needs in Low to Medium Income Countries of the World

3.6 Value Chain Analysis

3.7 Porter’s Five Forces Analysis: Global Hospital Infection Therapeutics Market

3.7.1 Bargaining Power of Suppliers

3.7.2 Bargaining Power of Buyers

3.7.3 Threat of Substitutes

3.7.4 Threat of New Entrants

3.7.5 Competitive Rivalry

3.8 Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography

3.9 Competitive Landscape

3.9.1 Market Share Analysis by Key Players: Hospital Infection Therapeutics Market, 2013 (Value %)

 

Chapter 4 Hospital Infection Therapeutics Market, by Drug Type

4.1 Overview

4.1.1 Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 – 2020 (USD Million)

4.1.2 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)

4.2 Antibacterial Drugs

4.2.1 Global Antibacterial Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)

4.3 Antiviral Drugs

4.3.1 Global Antiviral Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)

4.4 Antifungal Drugs

4.4.1 Global Antifungal Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)

4.5 Pipeline Analysis: Market Forecast

4.5.1 Amikacin Inhale

4.5.1.1 Global Amikacin Inhale Market Revenue (Expected), 2016 – 2020 (USD Million)

4.5.2 CAZ AVI (Ceftazidime/avibactum)

4.5.2.1 Global CAZ AVI Market Revenue (Expected), 2015 – 2020 (USD Million)

4.5.3 Ceftolozane/Tazobactam

4.5.3.1 Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 – 2020 (USD Million)

4.5.4 Dalvance (dalbavancin)

4.5.4.1 Global Dalvance (dalbavancin) Market Revenue (Expected), 2016 – 2020 (USD Million)

4.5.5 Delafloxacin (RX-3341)

4.5.5.1 Global Delafloxacin Market Revenue (Expected), 2015 – 2020 (USD Million)

4.5.6 Eravacycline (TP-434)

4.5.6.1 Global Eravacycline Market Revenue (Expected), 2017 – 2020 (USD Million)

4.5.7 MK-3415A

4.5.7.1 Global MK-3415A Market Revenue (Expected), 2016 – 2020 (USD Million)

4.5.8 Oritavancin

4.5.8.1 Global Oritavancin Market Revenue (Expected), 2017 – 2020 (USD Million)

4.5.9 Plazomicin

4.5.9.1 Global Plazomicin Market Revenue (Expected), 2017 – 2020 (USD Million)

4.5.10 Surotomycin (CB-315)

4.5.10.1 Global Surotomycin Market Revenue (Expected), 2017 – 2020 (USD Million)

4.5.11 Tedizolid (TR-701)

4.5.11.1 Global Tedizolid Market Revenue (Expected), 2015 – 2020 (USD Million)

 

Chapter 5 Hospital Infection Therapeutics Market, by Major Infections

5.1 Overview

5.1.1 Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 – 2020 (USD Million)

5.1.2 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)

5.2 Hospital-Acquired Pneumonia (HAP)

5.2.1 Global HAP Therapeutics Market Revenue, 2012 – 2020 (USD Million)

5.3 Surgical Site Infections (SSIs)

5.3.1 Global Surgical Site Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

5.4 Urinary Tract Infections (UTIs)

5.4.1 Global UTI Therapeutics Market Revenue, 2012 – 2020 (USD Million)

5.5 Gastrointestinal Disorders

5.5.1 Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 – 2020 (USD Million)

5.6 Bloodstream Infections

5.6.1 Global Bloodstream Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

5.7 Other Hospital Infections

5.7.1 Global Other Hospital Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

 

Chapter 6 Hospital infection therapeutics Market, by Geography

6.1 Overview

6.1.1 Global Hospital infection therapeutics Market Revenue, by Geography, 2012 – 2020 (USD Million)

6.2 North America

6.2.1 North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

6.3 Europe

6.3.1 Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

6.4 Asia Pacific

6.4.1 Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

6.5 Rest of the World (RoW)

6.5.1 RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

 

Chapter 7 Recommendations

 

Chapter 8 Company Profiles

8.1 Actavis plc

8.1.1 Company Overview

8.1.2 Financial Overview

8.1.3 Product Portfolio

8.1.4 Business Strategies

8.1.5 Recent Developments

8.2 AstraZeneca plc

8.2.1 Company Overview

8.2.2 Financial Overview

8.2.3 Product Portfolio

8.2.4 Business Strategies

8.2.5 Recent Developments

8.3 Bayer AG

8.3.1 Company Overview

8.3.2 Financial Overview

8.3.3 Product Portfolio

8.3.4 Business Strategies

8.3.5 Recent Developments

8.4 Bristol-Myers Squibb Company

8.4.1 Company Overview

8.4.2 Financial Overview

8.4.3 Product Portfolio

8.4.4 Business Strategies

8.4.5 Recent Developments

8.5 Cubist Pharmaceuticals, Inc.

8.5.1 Company Overview

8.5.2 Financial Overview

8.5.3 Product Portfolio

8.5.4 Business Strategies

8.5.5 Recent Developments

8.6 GlaxoSmithKline plc

8.6.1 Company Overview

8.6.2 Financial Overview

8.6.3 Product Portfolio

8.6.4 Business Strategies

8.6.5 Recent Developments

8.7 Johnson & Johnson Services, Inc.

8.7.1 Company Overview

8.7.2 Financial Overview

8.7.3 Product Portfolio

8.7.4 Business Strategies

8.7.5 Recent Developments

8.8 Merck & Co., Inc.

8.8.1 Company Overview

8.8.2 Financial Overview

8.8.3 Product Portfolio

8.8.4 Business Strategies

8.8.5 Recent Developments

8.9 Pfizer, Inc.

8.9.1 Company Overview

8.9.2 Financial Overview

8.9.3 Product Portfolio

8.9.4 Business Strategies

8.9.5 Recent Developments

8.10 Sanofi

8.10.1 Company Overview

8.10.2 Financial Overview

8.10.3 Product Portfolio

8.10.4 Business Strategies

8.10.5 Recent Developments

List of Table

 

FIG. 1 Hospital Infection Therapeutics: Market Segmentation

FIG. 2 Global Hospital Infection Therapeutics Market, by Drug Type, 2013 (USD Million)

FIG. 3 Global Hospital Infection Therapeutics Market, by Major Infections, 2013 (USD Million)

FIG. 4 Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)

FIG. 5 Global Hospital Infection Therapeutics Market: Event Impact Analysis

FIG. 6 Global Hospital Infection Therapeutics Market, Value Chain Analysis

FIG. 7 Porter’s Five Forces Analysis: Global Hospital Infection Therapeutics Market, 2012 - 2020

FIG. 8 Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography (2013)

FIG. 9 Market Share Analysis: Hospital Infection Therapeutics Market, 2013 (Value %)

FIG. 10 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)

FIG. 11 Global Antibacterial Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)

FIG. 12 Global Antiviral Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)

FIG. 13 Global Antifungal Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)

FIG. 14 Global Amikacin Inhale Market Revenue (Expected), 2016 – 2020 (USD Million)

FIG. 15 Global CAZ AVI Market Revenue (Expected), 2015 – 2020 (USD Million)

FIG. 16 Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 – 2020 (USD Million)

FIG. 17 Global Dalvance (Dalbavancin) Market Revenue (Expected), 2016 – 2020 (USD Million)

FIG. 18 Global Delafloxacin Market Revenue (Expected), 2015 – 2020 (USD Million)

FIG. 19 Global Eravacycline Market Revenue (Expected), 2017 – 2020 (USD Million)

FIG. 20 Global MK-3415A Market Revenue (Expected), 2016 – 2020 (USD Million)

FIG. 21 Global Oritavancin Market Revenue (Expected), 2017 – 2020 (USD Million)

FIG. 22 Global Plazomicin Market Revenue (Expected), 2017 – 2020 (USD Million)

FIG. 23 Global Surotomycin Market Revenue (Expected), 2017 – 2020 (USD Million)

FIG. 24 Global Tedizolid Market Revenue (Expected), 2015 – 2020 (USD Million)

FIG. 25 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)

FIG. 26 Global HAP Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 27 Global Surgical Site Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 28 Global UTI Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 29 Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 30 Global Bloodstream Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 31 Global Other Hospital Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 32 North America Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 33 Europe Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 34 Asia Pacific Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 35 RoW Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 36 Actavis plc: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 37 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 38 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 39 Bristol-Myers Squibb Company: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 40 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 41 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 42 Johnson & Johnson: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 43 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 44 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 45 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *